Gemzar® More Effective than Mutamycin® for Recurrent Superficial Bladder Cancer (10/23/2009)
Researchers from Italy have reported that intrabladder treatment with Gemzar® (gemcitabine) is more effective than Mutamycin® (mitomycin C) for the treatment of recurrent bladder cancer. The details of this randomized trial were published early online in the Journal of Clinical Oncology on October 19.

Multimodality Therapy with Hyperthermia Promising for High-risk Bladder Cancer (10/22/2009)
Researchers from Germany have reported that a strategy of transurethral resection followed by chemoradiotherapy with regional deep hyperthermia results in local recurrence-free survival of 85% in patients with high-risk Stage I and II bladder cancer. The details of this study were published early online in Radiotherapy and Oncology on October 19, 2009.

Arsenic Exposure May Be Related to Survival of Patients with Bladder Cancer (10/21/2009)
Researchers from Dartmouth Medical School have reported that patients with bladder cancer with high arsenic exposure had a lower survival rate than patients with bladder cancer without a high arsenic exposure. The details of this study appeared in an early online publication in the World Journal of Urology on October 16, 2009.

Thermo-chemotherapy May Improve Outcomes of Patients with Superficial Bladder Cancer Failing BCG (9/16/2009)
Researchers from Israel have reported that thermo-chemotherapy with mitomycin C in patients with recurrent superficial bladder cancer after treatment with Bacillus Calmette-Guerin (BCG) results in an 85% one-year disease-free survival (DFS) rate. The details of this study appeared in the October 2009 issue of the Journal of Urology.

High Time Costs for Informal Care Givers of Cancer Patients (9/10/2009)
Researchers from the National Cancer Institute (NCI) have reported that the time spent by informal caregivers is significant and an important component in the overall burden of cancer care. The details of this study appeared in the September 4, 2009 issue of Cancer.